The cost of waiting: caffeine for hypoxic-ischemic encephalopathy
Late pregnancy- and birth-related complications cause severe injury to the newborn clinically presenting as neonatal encephalopathy. One million die and many more suffer lifelong motor and/or cognitive disability. 1 In high-income countries, therapeutic hypothermia (TH) is the only standard treatment, reducing death or adverse neurodevelopmental outcomes by approximately 30%. 2 Yet 35% to 40% of infants do not benefit, partly because neonatal encephalopathy has heterogeneous etiologies, and TH has not improved outcomes to the same extent in low- and middle-income countries (LMICs). 3 Therapies which are effective without TH are particularly needed as it would be applicable to LMIC countries. 4
Authors
- Marianne Thoresen (ORCID: https://orcid.org/0000-0002-9615-9109)
- Hemmen Sabir (ORCID: https://orcid.org/0000-0002-4225-3554)
- Emin Maltepe (ORCID: https://orcid.org/0000-0002-1271-7565)
- Eleanor J. Molloy (ORCID: https://orcid.org/0000-0001-6798-2158)
- Ulrika Ådén (ORCID: https://orcid.org/0000-0002-0650-3173)
- Maria Eugenia Bernis
Institutions
- Linköping University (SE)
- Karolinska University Hospital (SE)
- University of Bonn (DE)
- University of California, San Francisco (US)
- University of Oslo (NO)
- University Hospital Bonn (DE)
- German Center for Neurodegenerative Diseases (DE)
- Karolinska Institutet (SE)
- Children's Health Ireland at Crumlin (IE)
- Temple Street Children's University Hospital (IE)
- Coombe Women & Infants University Hospital (IE)
Publication Details
- Journal
- Pediatric Research
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1038/s41390-026-05683-0
- Primary Topic
- Neonatal and fetal brain pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00